Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, ra... by Xu, Jianming, Prof, Kato, Ken, MD, Raymond, Eric, Prof, Hubner, Richard A, BM BCh, Shu, Yongqian, Prof, Pan, Yueyin, Prof, Park, Sook Ryun, Prof, Ping, Lu, MD, Jiang, Yi, MD, Zhang, Jingdong, Prof, Wu, Xiaohong, MD, Yao, Yuanhu, MD, Shen, Lin, Prof, Kojima, Takashi, Prof, Gotovkin, Evgeny, MD, Ishihara, Ryu, MD, Wyrwicz, Lucjan, Prof, Van Cutsem, Eric, Prof, Jimenez-Fonseca, Paula, MD, Lin, Chen-Yuan, MD, Wang, Lei, MD, Shi, Jingwen, PhD, Li, Liyun, MD, Yoon, Harry H, Prof

Get full text

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial by Vergote, Ignace, PhD, Scambia, Giovanni, MD, O'Malley, David M, MD, Van Calster, Ben, PhD, Park, Sang-Yoon, PhD, del Campo, Josep M, MD, Meier, Werner, PhD, Bamias, Aristotelis, PhD, Colombo, Nicoletta, MD, Wenham, Robert M, MD, Covens, Al, MD, Marth, Christian, PhD, Raza Mirza, Mansoor, MD, Kroep, Judith R, MD, Ma, Haijun, PhD, Pickett, Cheryl A, PhD, Monk, Bradley J, MD

Get full text